Moderate dilution risk offset by potential partnerships or upside from trial success. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a reasonably de-risked high potential play in obesity treatments.

The opportunity for Viking Therapeutics is to capture some of the upside from those combined $1 trillion market caps, though these biopharmas aren't entirely focused on weight-loss drugs.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style ...

A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. That figure was ...

Viking Therapeutics' VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given ...

This group includes Amgen (NASDAQ: AMGN) and Viking Therapeutics (NASDAQ: VKTX), two drugmakers that have produced phase 2 clinical trial data for their leading weight management candidates.